VAERS accepts reports of adverse events and reactions that occur following vaccination. Healthcare providers, vaccine manufacturers, and the public can submit reports to the system. While very important in monitoring vaccine safety, VAERS reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. In large part, reports to VAERS are voluntary, which means they are subject to biases. This creates specific limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind.
The strengths of VAERS are that it is national in scope and can quickly provide an early warning of a safety problem with a vaccine. As part of CDC and FDA’s multi-system approach to post-licensure vaccine safety monitoring, VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as “safety signals.” If a safety signal is found in VAERS, further studies can be done in safety systems such as the CDC’s Vaccine Safety Datalink (VSD) or the Clinical Immunization Safety Assessment (CISA) project. These systems do not have the same scientific limitations as VAERS, and can better assess health risks and possible connections between adverse events and a vaccine.
Key considerations and limitations of VAERS data:
VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.
blood thrombosis rate at 1,600 units; C-reactive protein high infectious: infectious rate; more severe breathing (due)/heavier breathing (dyspnoea); vomiting twice; nausea; Strong distressing headache/severe disrupting headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from the Regulatory Authority-WEB. Regulatory number: PL-URPL-DML-MLP.4401.2.10102.2021 (RA). Other Case identifier(s): L15584\2021 (RA). A 31-year-old female patient received BNT162b2 (COMIRNATY), on 23Aug2021 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: C-REACTIVE PROTEIN INCREASED (non-serious) with onset 24Aug2021 at 12:38, outcome "unknown", described as "C-reactive protein high infectious: infectious rate"; HEADACHE (non-serious) with onset 24Aug2021 at 12:38, outcome "unknown", described as "Strong distressing headache/severe disrupting headache"; THROMBOSIS (hospitalization, medically significant) with onset 24Aug2021 at 12:38, outcome "unknown", described as "blood thrombosis rate at 1,600 units"; DYSPNOEA (non-serious) with onset 24Aug2021 at 12:38, outcome "unknown", described as "more severe breathing (due)/heavier breathing (dyspnoea) "; NAUSEA (non-serious) with onset 24Aug2021 at 12:38, outcome "unknown"; VOMITING (non-serious) with onset 24Aug2021 at 12:38, outcome "unknown", described as "vomiting twice". Clinical course: Patient was hospitalized with hospitalization period from 24Aug2021 to today. The patient was hospitalized for thrombosis (start date: 24Aug2021). The patient underwent the following laboratory tests and procedures: Coagulation factor: (24Aug2021) 1600, notes: units; C-reactive protein: (24Aug2021) high. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
|COVID19 (COVID19 (PFIZER-BIONTECH))||Unknown||COVID19||PFIZER\BIONTECH||Unknown||Unknown|
|LAB_DATA:||Test Date: 20210824; Test Name: blood clotting index; Result Unstructured Data: Test Result:1600; Comments: units; Test Date: 20210824; Test Name: C-reactive protein; Result Unstructured Data: Test Result:high|